CORPORATE IMAGE AND BRAND PERFORMANCE OF KENYAN UNIVERSITIES

The highly competitive arena of the higher education sector implies the need for a good corporate image. Corporate image is recognized in the literature to have a positive impact on customer loyalty and is also a great way of differentiating an organization from its competitors as well stimulating consumers purchase. The higher education sectors’ products and services are increasingly similar today hence the need for the institutions to devise strategies to differentiate their products. Literature acknowledges the role of corporate image as an asset, which could give an organization a chance to differentiate itself with hope of maximizing its market share, acquiring new customers retaining existing ones, as well as counteracting the competitors’ actions in order to ensure success and improved performance. Organizations in the service industry are in business of creating outstanding service experiences for their customers. The management of corporate image however, is not an easy one especially in the service industry given the intangibility nature of services. An organization’s proper management of its corporate image can add value to a firm in a variety ways. Conversely, a negative image can destroy an organization’s reputation and isolate their customers. Empirical study results on corporate image and brand performance relationship however report mixed findings hence the need for the current study. This study investigated the relationship between corporate image and brand performance of Kenyan Universities. Data for the study were collected using a semi-structured questionnaire. The findings of the study support the notion that corporate image impacts brand performance. This therefore implies that an organization that invests in brand marketing activities relating to corporate image should experience enhanced brand performance. The study’s contribution to the higher education sector is in terms of addition to the body of knowledge. It also provides policy and managerial implications. The study only covered Kenyan universities. A similar study could also be carried out in the future focusing on all universities. Future studies could also focus on other sectors other than the higher education sector

Corporate Visual Identity Systems and Brand Performance Of Kenyan Universities

There is a heightened interest towards corporate identity with organisations realising that it is indispensable if they wish to create a competitive advantage in the global environment in which they are operating in. Globalization of the higher education sector implies that Kenyan universities need to market themselves in a climate of competition that is not only local but global. They have to attract high quality students and academic staff at an international level hence competition is no longer limited within national borders.Faced with competition, universities are developing strategies for competitiveness and survival such as management of corporate visual identity systems in order to positively impact on their corporate image and performance.This study investigated the relationship between corporate visual identity systems (CVIS) and brand performance of Kenyan Universities. Data were collected from the universities’ corporate affairs or public relations managers or their equivalent as the key informants using a semi structured questionnaire. The results of the study revealed direct effect of corporate visual identity systems on brand performance to be statistically significant. The beta coefficient was 0.447 and this was highly statistically significant (p-value=.000).This variable explained 41.1% of the variation in brandperformance. The empirical finding supports the notion that corporate visual identity systems drive brand performance. Consequently, by investing in brand marketing activities that span all the corporate visual identity facets, universities should experience enhanced brand performance..The study has made contribution to theory, policy andpractice in corporate visual identity systems specifically in the higher education sector. The study was limited to Kenyan universities. Replication of the study with all universities being included could serve as a useful reference for future research. Future studies could also focus on other sectors other than the higher education sector.Key Words: Corporate Visual Identity Systems , Organizations, Brand Performanc

Corporate Image and Brand Performance of Kenyan Universities

The highly competitive arena of the higher education sector implies the need for a goodcorporate image. Corporate image is recognized in the literature to have a positiveimpact on customer loyalty and is also a great way of differentiating an organizationfrom its competitors as well stimulating consumers purchase. The higher educationsectors’ products and services are increasingly similar today hence the need for theinstitutions to devise strategies to differentiate their products. Literature acknowledgesthe role of corporate image as an asset which could give an organization a chance todifferentiate itself with hope of maximizing its market share, acquiring new customersretaining existing ones, as well as counteracting the competitors’ actions in order toensure success and improved performance. Organizations in the service industry are in business of creating outstanding service experiences for their customers. The management of corporate image however, is not an easy one especially in the serviceindustry given the intangibility nature of services. An organization’s propermanagement of its corporate image, can add value to a firm in a variety ways.Conversely, a negative image can destroy an organization’s reputation and isolate theircustomers. Empirical study results on corporate image and brand performancerelationship however report mixed findings hence the need for the current study. Thisstudy investigated the relationship between corporate image and brand performance ofKenyan Universities. Data for the study were collected using a semi structuredquestionnaire. The study focused on key informants mainly universities’ corporateaffairs or public relations managers or their equivalent. The study findings indicate thatthe relationship between corporate image and brand performance is statistically significant. It explained 45.1% of variation (=.451). The standardized regressioncoefficient (β) value of the computed (composite index) scores of corporate image was.672 with a t-test value of 5.290 and a significance level of p-value=.000. The findings ofthe study support the notion that corporate image impacts brand performance. Thistherefore implies that an organization that invests in brand marketing activities relating to corporate image should experience enhanced brand performance. The study’scontribution to the higher education sector is in terms of addition to the body ofknowledge. It also provides policy and managerial implications. The study only coveredKenyan universities. A similar study could also be carried out in the future focusing o

Alzheimer\u27s Disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology

Introduction Cerebrospinal fluid (CSF) biomarkers, although of established utility in the diagnostic evaluation of Alzheimer’s disease (AD), are known to be sensitive to variation based on pre-analytical sample processing. We assessed whether gravity droplet collection versus syringe aspiration was another factor influencing CSF biomarker analyte concentrations and reproducibility. Methods Standardized lumbar puncture using small calibre atraumatic spinal needles and CSF collection using gravity fed collection followed by syringe aspirated extraction was performed in a sample of elderly individuals participating in a large long-term observational research trial. Analyte assay concentrations were compared. Results For the 44 total paired samples of gravity collection and aspiration, reproducibility was high for biomarker CSF analyte assay concentrations (concordance correlation [95%CI]: beta-amyloid1-42 (Aβ42) 0.83 [0.71 - 0.90]), t-tau 0.99 [0.98 - 0.99], and phosphorylated tau (p-tau) 0.82 [95 % CI 0.71 - 0.89]) and Bonferroni corrected paired sample t-tests showed no significant differences (group means (SD): Aβ42 366.5 (86.8) vs 354.3 (82.6), p = 0.10; t-tau 83.9 (46.6) vs 84.7 (47.4) p = 0.49; p-tau 43.5 (22.8) vs 40.0 (17.7), p = 0.05). The mean duration of collection was 10.9 minutes for gravity collection andaspiration. Conclusions Our results demonstrate that aspiration of CSF is comparable to gravity droplet collection for AD biomarker analyses but could considerably accelerate throughput and improve the procedural tolerability for assessment of CSF biomarkers. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

Introduction: The multiorgan impact of moderate to severe coronavirus infections in the post-acute phase is still poorly understood. We aimed to evaluate the excess burden of multiorgan abnormalities after hospitalisation with COVID-19, evaluate their determinants, and explore associations with patient-related outcome measures. Methods: In a prospective, UK-wide, multicentre MRI follow-up study (C-MORE), adults (aged ≥18 years) discharged from hospital following COVID-19 who were included in Tier 2 of the Post-hospitalisation COVID-19 study (PHOSP-COVID) and contemporary controls with no evidence of previous COVID-19 (SARS-CoV-2 nucleocapsid antibody negative) underwent multiorgan MRI (lungs, heart, brain, liver, and kidneys) with quantitative and qualitative assessment of images and clinical adjudication when relevant. Individuals with end-stage renal failure or contraindications to MRI were excluded. Participants also underwent detailed recording of symptoms, and physiological and biochemical tests. The primary outcome was the excess burden of multiorgan abnormalities (two or more organs) relative to controls, with further adjustments for potential confounders. The C-MORE study is ongoing and is registered with ClinicalTrials.gov, NCT04510025. Findings: Of 2710 participants in Tier 2 of PHOSP-COVID, 531 were recruited across 13 UK-wide C-MORE sites. After exclusions, 259 C-MORE patients (mean age 57 years [SD 12]; 158 [61%] male and 101 [39%] female) who were discharged from hospital with PCR-confirmed or clinically diagnosed COVID-19 between March 1, 2020, and Nov 1, 2021, and 52 non-COVID-19 controls from the community (mean age 49 years [SD 14]; 30 [58%] male and 22 [42%] female) were included in the analysis. Patients were assessed at a median of 5·0 months (IQR 4·2–6·3) after hospital discharge. Compared with non-COVID-19 controls, patients were older, living with more obesity, and had more comorbidities. Multiorgan abnormalities on MRI were more frequent in patients than in controls (157 [61%] of 259 vs 14 [27%] of 52; p<0·0001) and independently associated with COVID-19 status (odds ratio [OR] 2·9 [95% CI 1·5–5·8]; padjusted=0·0023) after adjusting for relevant confounders. Compared with controls, patients were more likely to have MRI evidence of lung abnormalities (p=0·0001; parenchymal abnormalities), brain abnormalities (p<0·0001; more white matter hyperintensities and regional brain volume reduction), and kidney abnormalities (p=0·014; lower medullary T1 and loss of corticomedullary differentiation), whereas cardiac and liver MRI abnormalities were similar between patients and controls. Patients with multiorgan abnormalities were older (difference in mean age 7 years [95% CI 4–10]; mean age of 59·8 years [SD 11·7] with multiorgan abnormalities vs mean age of 52·8 years [11·9] without multiorgan abnormalities; p<0·0001), more likely to have three or more comorbidities (OR 2·47 [1·32–4·82]; padjusted=0·0059), and more likely to have a more severe acute infection (acute CRP >5mg/L, OR 3·55 [1·23–11·88]; padjusted=0·025) than those without multiorgan abnormalities. Presence of lung MRI abnormalities was associated with a two-fold higher risk of chest tightness, and multiorgan MRI abnormalities were associated with severe and very severe persistent physical and mental health impairment (PHOSP-COVID symptom clusters) after hospitalisation. Interpretation: After hospitalisation for COVID-19, people are at risk of multiorgan abnormalities in the medium term. Our findings emphasise the need for proactive multidisciplinary care pathways, with the potential for imaging to guide surveillance frequency and therapeutic stratification

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Acculturation and adaptation : orientation program for exchange students.

This applied research paper attempts to analyze the problems faced by the exchange students in adapting to the local environment so that a more effective orientation program can be designed for these students to smoothen their transition process. For this purpose, two surveys were conducted; one to the exchange students and one to the universities worldwide. We also came up with a student handbook that incorporates more information on Singapore and NTU